Ubiquigent™ has the assays, expertise, and capabilities to drive forward every step in the drug discovery workflow for DUB-focused therapeutic applications, from targeting DUBs as the drug target to harnessing them for the modulation or stabilisation of a given disease protein.
End-to-end platform for DUB-focused drug discovery and development
Our specialised drug discovery platform and long-standing expertise is empowering scientists to develop DUB inhibitors, DUB-targeting PROTACs, and DUBTACs into exciting new medicines
Chemistry expertise to design novel compounds
Proprietary DUB-targeting compounds
Novel compounds to provide new starting points for DUB-focused drug discovery programmes
Ubiquigent has a growing collection of novel DUB-targeting compounds that have been evaluated across our suite of comprehensive biochemical and cellular assays. These compounds represent a valuable resource for identifying new starting points for DUB-focused drug discovery programmes.
Highly experienced chemists in DUB drug discovery
Our chemists have worked on the design and development of DUB-binding ligands for our internal pipeline and on behalf of our clients
Ubiquigent chemists are experienced at applying computational and medicinal skills to the design of DUB ligands, encompassing covalent and non-covalent compounds, and compounds with an allosteric mechanism of action. They also have substantial experience in developing orally bioavailable heterobifunctional molecules.
Access to a range of relevant technologies through our growing network of collaborators and industry experts, including in structural biology
Ubiquigent has established a network of academic and industrial partners to augment our own experience, including structural biology, mass spectrometry and individual DUB target-based expertise. These existing partnerships alongside new collaborations, as appropriate, can be leveraged to offer our clients an even more comprehensive DUB-focused partnership.